Protagonist Therapeutics(PTGX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PTGX Protagonist Therapeutics

Closed 07-10 16:00:00 EDT

131.42

-6.22

-4.52%

盘后131.42

+0.000.00%

19:55 EDT

High137.12	Low130.64	Vol1.06M
Open137.12	D1 Closing137.64	Amplitude4.71%
Mkt Cap8.45B	Tradable Cap8.22B	Total Shares64.31M
T/O139.93M	T/O Rate1.70%	Tradable Shares62.52M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PTGX","market":"US","secType":"STK","nameCN":"Protagonist Therapeutics","latestPrice":131.42,"timestamp":1783713600000,"preClose":137.64,"halted":0,"volume":1060849,"hourTrading":{"tag":"盘后","latestPrice":131.42,"preClose":131.42,"latestTime":"19:55 EDT","volume":123876,"amount":16279905.16,"timestamp":1783727711056,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.04519035164196454,"floatShares":62520047,"shares":64305185,"eps":-1.791415,"marketStatus":"Closed","change":-6.22,"latestTime":"07-10 16:00:00 EDT","open":137.12,"high":137.12,"low":130.64,"amount":139929250.51492,"amplitude":0.047079,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.791415,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1783929600000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1470888000000,"exchange":"NASDAQ","adjPreClose":137.64,"preHourTrading":{"tag":"盘前","latestPrice":138.15,"preClose":137.64,"latestTime":"08:55 EDT","volume":37,"amount":5084.86005,"timestamp":1783688150524,"change":0.51,"changeRate":0.003705,"amplitude":0.010099},"postHourTrading":{"tag":"盘后","latestPrice":131.42,"preClose":131.42,"latestTime":"19:55 EDT","volume":123876,"amount":16279905.16,"timestamp":1783727711056,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.006966,"impliedVol":0.6437,"impliedVolPercentile":0.9442},"requestUrl":"/m/hq/s/PTGX/wiki","defaultTab":"wiki","newsList":[{"id":"2650190454","title":"Will Icotyde’s Launch and Rusfertide’s Priority Review Change Protagonist Therapeutics’ (PTGX) Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2650190454","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650190454?lang=en_us&edition=fundamental","pubTime":"2026-07-10 11:36","pubTimestamp":1783654616,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics has already secured FDA approval and a U.S. launch for its psoriasis drug Icotyde, while its polycythemia vera candidate rusfertide is under FDA priority review with an August 2026 action date.\nThis combination of an on-market product and a late-stage asset under priority review is reshaping how investors view Protagonist’s development-to-commercial transition.\nWe’ll now explore how Icotyde’s U.S. launch and the evolving outlook for rusfertide are influencing...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/will-icotydes-launch-and-rusfertides-priority-review-change","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/will-icotydes-launch-and-rusfertides-priority-review-change","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PTGX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149536299","title":"Movement Alert｜Protagonist Therapeutics Rises 6.35% in Regular Trading, Truist Raises Price Target to $145","url":"https://stock-news.laohu8.com/highlight/detail?id=1149536299","media":"Market Focus","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149536299?lang=en_us&edition=fundamental","pubTime":"2026-07-08 02:11","pubTimestamp":1783447893,"startTime":"0","endTime":"0","summary":"On July 7, Protagonist Therapeutics rose 6.35% in regular trading, trading at $139.975/share, with turnover of $117 million. The rally was driven by investment bank Truist significantly raising its...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649982655","title":"Protagonist Therapeutics is Maintained at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2649982655","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649982655?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:47","pubTimestamp":1783424820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PTGX/analyst-ratings(END) Dow Jones NewswiresJuly 07, 2026 07:47 ET","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649989733","title":"Protagonist Therapeutics Inc : Truist Securities Raises Target Price to $145 from $121","url":"https://stock-news.laohu8.com/highlight/detail?id=2649989733","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649989733?lang=en_us&edition=fundamental","pubTime":"2026-07-07 18:16","pubTimestamp":1783419368,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nFWN4390C7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTGX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649896139","title":"Truist Raises Price Target on Protagonist Therapeutics to $145 From $121, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2649896139","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649896139?lang=en_us&edition=fundamental","pubTime":"2026-07-07 18:12","pubTimestamp":1783419168,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics (PTGX) has an average rating of buy and mean price target of $119.15, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648576079","title":"The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following Rusfertide Review Optimism And New Hires – Learn Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2648576079","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648576079?lang=en_us&edition=fundamental","pubTime":"2026-07-02 11:45","pubTimestamp":1782963946,"startTime":"0","endTime":"0","summary":"In late June 2026, Protagonist Therapeutics granted stock-based inducement awards to three new employees and received upbeat analyst commentary emphasizing upcoming PN-881 data and the Rusfertide regulatory decision. \nThis combination of fresh talent incentives and growing external confidence in the company’s pipeline has sharpened investor focus on its development and commercialization plans.\nWith this backdrop, we'll examine how enthusiasm around Rusfertide’s regulatory review shapes...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/the-bull-case-for-protagonist-therapeutics-ptgx-could-change-3","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/the-bull-case-for-protagonist-therapeutics-ptgx-could-change-3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648525252","title":"Protagonist Therapeutics Grants Inducement Awards for 8,650 Share Options, 2,275 Rsus to New Hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2648525252","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648525252?lang=en_us&edition=fundamental","pubTime":"2026-07-02 04:05","pubTimestamp":1782936322,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics grants inducement awards for 8,650 share options, 2,275 RSUs to new hiresProtagonist Therapeutics granted inducement equity awards on June 30, 2026 to three newly hired employ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL3dMSCK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTGX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648563378","title":"Medicare Coverage Could Put These Obesity Drug Stocks In Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2648563378","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648563378?lang=en_us&edition=fundamental","pubTime":"2026-06-30 23:17","pubTimestamp":1782832637,"startTime":"0","endTime":"0","summary":"The obesity and metabolic drug space is suddenly in the spotlight, and not just because of headlines around GLP-1 treatments. A Supreme Court ruling on executive power, Medicare’s move to start covering obesity drugs, and a record close for the Dow are all feeding into a new conversation about where risk and opportunity may sit in this corner of healthcare. This article looks at 3 stocks from our Healthcare Sector, Obesity and Metabolic Drug Manufacturers screener that appear particularly...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/medicare-coverage-could-put-these-obesity-drug-stocks-in-foc","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/medicare-coverage-could-put-these-obesity-drug-stocks-in-foc","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MDGL","BK4139","BK4585","PTGX","RYTM","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646380797","title":"Insider Cashes In: Major Protagonist Therapeutics Stock Sale Shakes Up Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2646380797","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646380797?lang=en_us&edition=fundamental","pubTime":"2026-06-26 10:01","pubTimestamp":1782439276,"startTime":"0","endTime":"0","summary":"New insider activity at Protagonist Therapeutics ( ($PTGX) ) has taken place on June 25, 2026. Director William Waddill of Protagonist Therapeutics...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/insider-cashes-in-major-protagonist-therapeutics-stock-sale-shakes-up-investors-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/insider-cashes-in-major-protagonist-therapeutics-stock-sale-shakes-up-investors-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4211","ISBC","PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646338594","title":"Protagonist Therapeutics Director William D. Waddill Disposes of Common Shares Worth $1.06 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2646338594","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646338594?lang=en_us&edition=fundamental","pubTime":"2026-06-26 04:11","pubTimestamp":1782418263,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics director William D. Waddill disposes of common shares worth $1.06 millionProtagonist Therapeutics director William D. Waddill sold 9,000 common shares on June 23, 2026 at USD ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDL4PMSx4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Protagonist Therapeutics Director William D. Waddill Disposes of Common Shares Worth $1.06 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTGX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644715034","title":"Protagonist Therapeutics Stockholders Approve Directors and Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2644715034","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644715034?lang=en_us&edition=fundamental","pubTime":"2026-06-19 06:46","pubTimestamp":1781822786,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics ( ($PTGX) ) has shared an announcement. At its recent Annual Meeting, Protagonist Therapeutics’ stockholders elected two C...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/protagonist-therapeutics-stockholders-approve-directors-and-incentive-plan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/protagonist-therapeutics-stockholders-approve-directors-and-incentive-plan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644803988","title":"Protagonist Therapeutics shareholders approve 2026 equity incentive plan at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2644803988","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644803988?lang=en_us&edition=fundamental","pubTime":"2026-06-19 04:32","pubTimestamp":1781814721,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics held its annual meeting on June 17, 2026.Stockholders adopted the 2026 Equity Incentive Plan, replacing the 2016 plan, authorizing up to 650,000 new shares for equity awards.Stockholders also backed the slate of Class I director nominees, with terms running through the 2029 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagonist Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL6R6t4L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644767432","title":"Protagonist Therapeutics grants inducement equity awards for 18,700 shares at $112.46 strike","url":"https://stock-news.laohu8.com/highlight/detail?id=2644767432","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644767432?lang=en_us&edition=fundamental","pubTime":"2026-06-17 04:00","pubTimestamp":1781640017,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics granted inducement equity awards on June 15, 2026 to three newly hired employees.Awards total stock options for 14,800 shares, priced at $112.46, plus 3,900 restricted stock units.Options vest over four years: 25% after one year, then monthly over the next three years; RSUs vest 25% annually.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL704zyQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTGX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642256339","title":"Top Protagonist Therapeutics Insider Makes a Major Move With His Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2642256339","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642256339?lang=en_us&edition=fundamental","pubTime":"2026-06-12 10:09","pubTimestamp":1781230180,"startTime":"0","endTime":"0","summary":"New insider activity at Protagonist Therapeutics ( ($PTGX) ) has taken place on June 11, 2026. Director William Waddill of Protagonist Therapeutics...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-protagonist-therapeutics-insider-makes-a-major-move-with-his-shares-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-protagonist-therapeutics-insider-makes-a-major-move-with-his-shares-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642230865","title":"Protagonist Therapeutics director William D. Waddill disposes of USD 969,120 in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2642230865","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642230865?lang=en_us&edition=fundamental","pubTime":"2026-06-12 07:07","pubTimestamp":1781219249,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics director William D. Waddill sold 9,000 common shares on June 10 at USD 107.68, cutting his direct stake to 7,825 shares.He acquired 9,000 shares the same day via option exercises priced at USD 11.8 and USD 16.54.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagonist Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL23616q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Protagonist Therapeutics director William D. Waddill disposes of USD 969,120 in common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTGX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640135353","title":"Could New Rusfertide Data Presentations Subtly Reframe Protagonist Therapeutics' (PTGX) Core Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2640135353","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640135353?lang=en_us&edition=fundamental","pubTime":"2026-06-04 09:18","pubTimestamp":1780535882,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics recently highlighted that four abstracts on rusfertide in polycythemia vera, including Phase 3 VERIFY and long-term Phase 2 data, will be presented at the 2026 European Hematology Association Congress, while management also appeared at the Jefferies Global Healthcare Conference in New York.\nThe new data cuts from VERIFY and the long-running REVIVE and THRIVE extension studies offer a deeper look at rusfertide’s efficacy, safety and potential impact on cytoreductive...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/could-new-rusfertide-data-presentations-subtly-reframe-prota","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/could-new-rusfertide-data-presentations-subtly-reframe-prota","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640296052","title":"Protagonist Therapeutics director William D. Waddill disposes of 9,000 common shares worth $896,760","url":"https://stock-news.laohu8.com/highlight/detail?id=2640296052","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640296052?lang=en_us&edition=fundamental","pubTime":"2026-06-02 06:32","pubTimestamp":1780353121,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics director William D. Waddill sold 9,000 common shares at USD 99.64 on May 29, 2026.Sale followed a 9,000-share option exercise at USD 11.8, lifting his direct holdings to 16,825 shares before the sale.Waddill ended the day with 7,825 common shares, held directly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagonist Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL4jHRGT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Protagonist Therapeutics director William D. Waddill disposes of 9,000 common shares worth $896,760","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638298667","title":"Protagonist Therapeutics CEO Patel to speak at Jefferies Global Healthcare Conference fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2638298667","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638298667?lang=en_us&edition=fundamental","pubTime":"2026-05-28 19:05","pubTimestamp":1779966351,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics is set for fireside chats at two healthcare investor conferences in June 2026.Jefferies Global Healthcare Conference in New York on June 3, 2026 at 9:55 a.m. ET.Goldman Sachs 47th Annual Global Healthcare Conference in Miami on June 10, 2026 at 9:20 a.m. ET.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL4NVbd5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2471134879.HKD","BK4504","IE00BFXG1179.USD","LU2237443622.USD","IE0002270589.USD","LU2750360997.AUD","BK4552","IE0004086264.USD","LU0942090050.USD","LU1868837300.USD","BK4516","LU2471134796.USD","LU2237443549.SGD","LU2237443382.USD","LU2237443465.HKD","LU1868836757.USD","LU0345770308.USD","LU0048573561.USD","LU2265009873.SGD","LU0106831901.USD","BK4550","LU2237438978.USD","BK4127","IE00B19Z3581.USD","LU1668664300.SGD","LU1894683264.USD","BK4533","LU1868836914.USD","IE00B19Z3B42.SGD","LU0868494617.USD","LU2471134952.CNY","LU0742534661.SGD","IE00BSNM7G36.USD","GSX","LU1791807156.HKD","LU1804176565.USD","LU1868836591.USD","LU2237443978.SGD","LU0061475181.USD","IE0004091025.USD","LU0251131958.USD","LU0868494708.USD","LU2237443895.HKD","LU2750360641.GBP","LU2471134523.USD","BK4585","LU0251142724.SGD","LU1868837136.USD","PTGX","LU0345770993.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638669444","title":"J&J Mastered Cancer Biotech Deals on the Cheap. Can it Stay on the Cutting Edge? -- Heard on the Street -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2638669444","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638669444?lang=en_us&edition=fundamental","pubTime":"2026-05-28 17:30","pubTimestamp":1779960600,"startTime":"0","endTime":"0","summary":"Johnson & Johnson seems to have perfected the art of the biotech deal.Rather than spending billions on acquisitions, it has built much of its pharma empire through partnerships that capture huge upside for bargain prices.But there's a catch. A biotech partnership is a bit like an open relationship: Your partner can always fall in love with someone else.It's early days, but Big Pharma has been racing to own the technology. AbbVie, Bristol-Myers Squibb, AstraZeneca and Gilead have all made acquisitions in the space. Eli Lilly alone has agreed to spend more than $9 billion on two in-vivo companies in the past year. J&J tried to get ahead by joining up with Kelonia, a startup that engineered a virus to selectively target T cells inside the body. Then Lilly last month agreed to pay up to $7 billion to buy Kelonia outright -- based on data from a handful of patients -- and J&J's in-vivo partner suddenly belonged to a rival. A J&J spokesperson said in an email that in-vivo CAR-T remains one o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1074936037.SGD","BK4007","LU1674673691.USD","LU0345770308.USD","LU1585245621.USD","LU1043141123.HKD","CAR","HK0000306685.HKD","LU2089284900.SGD","LU2417539215.USD","HK0000320223.HKD","LU1430594728.SGD","LU0456855351.SGD","LU0122379950.USD","LU0472753341.HKD","PTGX","XBI","LU1934455863.HKD","BK4588","LU1935042991.SGD","LU0426417589.USD","LU2602419157.SGD","SG9999002224.SGD","LU0795875086.SGD","SG9999011175.SGD","LU1057294990.SGD","LU2750360641.GBP","LU1551013342.USD","01548","LU0203347892.USD","LU1718418525.SGD","BK1141","LU2089283258.USD","BK4534","ABBV","LU0057025933.USD","LU0820561909.HKD","LU1989771016.USD","LU0738911758.USD","LU0708994859.HKD","LU1280957306.USD","LU0545562505.USD","LU0965509283.SGD","LEGN","SG9999001440.SGD","LU1244550494.USD","LU1291159041.SGD","IE00BGHQF631.EUR","JNJ","IE0000B7K699.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637333285","title":"Genvor names Donald Kalkofen chief financial officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2637333285","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637333285?lang=en_us&edition=fundamental","pubTime":"2026-05-21 20:01","pubTimestamp":1779364862,"startTime":"0","endTime":"0","summary":"Genvor appointed Donald Kalkofen as chief financial officer on May 21, 2026, tasking him with financial strategy as it advances commercialization across agriculture, human health, and wellness.Kalkofen most recently served as CFO of Alpha Cognition, where he led preparations for its NASDAQ listing and built out banking, audit committee, and investor relations functions.He previously held CFO roles at Protagonist Therapeutics, Symantec, and West Coast Bancorp, where he took the bank public on NASDAQ.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL980qW7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","BK4585","IE00BN0W2W23.USD","ACOG","IE00BGHQF748.EUR","GNVR","BK4112","BK4139","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014039.USD","SG9999014013.SGD","LU2210150020.SGD","BK4588","IE00BKPKM429.USD","LU0314104364.USD","PTGX","NDAQ","LU2095319765.USD","SG9999014021.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.protagonist-inc.com","stockEarnings":[{"period":"1week","weight":0.0457},{"period":"1month","weight":0.3001},{"period":"3month","weight":0.3928},{"period":"6month","weight":0.7158},{"period":"1year","weight":1.6322},{"period":"ytd","weight":0.5759}],"compareEarnings":[{"period":"1week","weight":0.0093},{"period":"1month","weight":0.0199},{"period":"3month","weight":0.1063},{"period":"6month","weight":0.083},{"period":"1year","weight":0.2045},{"period":"ytd","weight":0.1023}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.030975},{"month":2,"riseRate":0.5,"avgChangeRate":0.004927},{"month":3,"riseRate":0.5,"avgChangeRate":0.077907},{"month":4,"riseRate":0.2,"avgChangeRate":-0.1188},{"month":5,"riseRate":0.7,"avgChangeRate":0.186258},{"month":6,"riseRate":0.8,"avgChangeRate":0.107488},{"month":7,"riseRate":0.6,"avgChangeRate":0.014781},{"month":8,"riseRate":0.777778,"avgChangeRate":0.16209},{"month":9,"riseRate":0.5,"avgChangeRate":0.00523},{"month":10,"riseRate":0.4,"avgChangeRate":0.039581},{"month":11,"riseRate":0.6,"avgChangeRate":0.076941},{"month":12,"riseRate":0.5,"avgChangeRate":0.014044}],"exchange":"NASDAQ","name":"Protagonist Therapeutics","nameEN":"Protagonist Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Protagonist Therapeutics(PTGX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Protagonist Therapeutics(PTGX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Protagonist Therapeutics,PTGX,Protagonist Therapeutics股票,Protagonist Therapeutics股票老虎,Protagonist Therapeutics股票老虎国际,Protagonist Therapeutics行情,Protagonist Therapeutics股票行情,Protagonist Therapeutics股价,Protagonist Therapeutics股市,Protagonist Therapeutics股票价格,Protagonist Therapeutics股票交易,Protagonist Therapeutics股票购买,Protagonist Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Protagonist Therapeutics(PTGX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Protagonist Therapeutics(PTGX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}